Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 7,591,601 $ 6,493,208
General and administrative 2,945,276 2,634,040
Total operating expenses 10,536,877 9,127,248
Loss from operations (10,536,877) (9,127,248)
Interest income 21,239 24,024
Net loss (10,515,638) (9,103,224)
Other comprehensive income:    
Foreign currency translation gain/(loss) (2,937) 4,713
Unrealized gain on investments 15,039 0
Comprehensive loss $ (10,503,536) $ (9,098,511)
Net loss per share:    
Basic and diluted $ (0.83) $ (0.73)
Weighted average shares outstanding:    
Basic and diluted 12,718,166 12,471,217